IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
This research study is investigating new ways to treat a type of cancer called metastatic uveal melanoma, which is eye melanoma that has spread to other parts of the body. The study aims to see if a new drug combination, IDE196 plus crizotinib, is more effective and safer than currently available treatments. Participants will be randomly assigned to receive either the new drug combination or one of the standard treatments chosen by their doctor. The study will carefully check how well the treatments shrink the cancer, how long people live, and any side effects they experience. This information will help doctors understand the best ways to care for patients with this condition.
एक नजर में
यह अध्ययन किस बारे में है?
This study is for people who have metastatic uveal melanoma, which is a type of eye cancer that has spread to other parts of the body. When cancer spreads, it can be more challenging to treat, so doctors are always looking for new and better options. This research is testing a new approach using a combination of two drugs, IDE196 and crizotinib. They want to see if this combination works better and is safer than some of the treatments doctors currently offer.
To do this, the study will compare the new drug combination with standard treatments like pembrolizumab, ipilimumab plus nivolumab, or dacarbazine. Patients taking part will be randomly assigned to one of these treatment groups. This random assignment helps ensure the study results are fair and reliable. The study is split into different stages (Phase 2 and Phase 3) to gradually gather information. First, they'll find the best dose of the new drug combination, and then they'll compare that dose more widely against the standard treatments.
The main goal is to find out if the new drug combination helps people live longer and if it can shrink the cancer effectively, all while keeping side effects manageable. By carefully comparing these different treatments, researchers hope to improve the care options available for people with metastatic uveal melanoma.
मुख्य निष्कर्ष
- This study is for advanced eye melanoma that has spread.
- It tests a new drug combination against usual treatments.
- Participation involves regular check-ups, blood tests, and scans.
- You'll be randomly assigned to a treatment group.
- The goal is to find better, safer treatments for this cancer.
कौन पात्र हो सकता है?
To be considered for this study, you would need to have a confirmed diagnosis of eye melanoma that has spread. Importantly, you shouldn't have received any previous treatment specifically for this advanced cancer, though some earlier treatments like surgery or radiation in a local area might be allowed.
Your general health would also be checked, including your organ function and overall well-being. You would need to be well enough to take the study medication and have a life expectancy of at least three months. There is also a specific blood test for something called HLA-A*02:01, and you would need to be negative for this marker.
Some things that might prevent you from joining include a history of other serious health conditions like certain heart problems, active infections, or if you've already had a similar type of drug. If you are pregnant or breastfeeding, you wouldn't be able to take part. The study also needs to make sure the standard treatments chosen by your doctor are suitable for you, so any reasons you couldn't take those would also be a factor.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- Do you have eye melanoma that has spread to other parts of your body?
- Have you not had any treatment specifically for this spread cancer before?
- Are you generally feeling well and able to carry out daily activities?
- Are you able to take study medicines safely?
- क्या आप वर्तमान में गर्भवती या स्तनपान नहीं करा रही हैं?
- Do you have good overall organ health (e.g., heart, kidneys, liver)?
भागीदारी में क्या शामिल है?
If you join this study, you will be randomly assigned to receive either the new drug combination (IDE196 + crizotinib) or one of the standard treatments chosen by your doctor. You won't get to choose which treatment you receive. You will have regular visits to the clinic for medical check-ups, blood tests, and scans (like CT or MRI) to see how your body is responding to the treatment and if the cancer is changing. These visits will also help monitor for any side effects. The medications will be given according to a specific schedule, which your study team will explain in detail. The total duration of your participation will depend on how you respond to the treatment and the study's design, but it will involve ongoing follow-up to monitor your health.
संभावित जोखिम और लाभ
स्थान (68)
- Honor Healthसत्यापित पोस्टकोडस्कॉट्सडेल, संयुक्त राज्य अमेरिका
- मूर्स कैंसर केंद्रसत्यापित पोस्टकोडला जोला, संयुक्त राज्य अमेरिका
- UCLA Medical Centerसत्यापित पोस्टकोडलॉस एंजेलेस, संयुक्त राज्य अमेरिका
- The Angeles Clinic and Research Instituteसत्यापित पोस्टकोडलॉस एंजेलेस, संयुक्त राज्य अमेरिका
- California Pacific Medical Center (CPMC)सत्यापित पोस्टकोडसैन फ्रांसिस्को, संयुक्त राज्य अमेरिका
- कैलिफोर्निया विश्वविद्यालय सैन फ्रांसिस्कोसत्यापित पोस्टकोडसैन फ्रांसिस्को, संयुक्त राज्य अमेरिका
- University of Colorado Cancer Centerसत्यापित पोस्टकोडऑरोरा, संयुक्त राज्य अमेरिका
- SCRI at HealthONEसत्यापित पोस्टकोडडेनवर, संयुक्त राज्य अमेरिका
- University of Miami Sylvester Comprehensive Cancer Centerसत्यापित पोस्टकोडमियामी, संयुक्त राज्य अमेरिका
- मोफिट कैंसर केंद्रसत्यापित पोस्टकोडटाम्पा, संयुक्त राज्य अमेरिका
- Northside Hospital Atlantaसत्यापित पोस्टकोडअटलांटा, संयुक्त राज्य अमेरिका
- आयोवा विश्वविद्यालयसत्यापित पोस्टकोडआयोवा सिटी, संयुक्त राज्य अमेरिका
सामान्य प्रश्न
What is metastatic uveal melanoma?
It's a type of eye cancer that has spread from the eye to other parts of your body.
'रैंडमली असाइंड' का क्या मतलब है?
It means you'll be put into a treatment group by chance, like flipping a coin, so the study is fair.
क्या मुझे पता चलेगा कि मुझे कौन सा उपचार मिल रहा है?
हाँ, यह एक 'ओपन-लेबल' अध्ययन है, जिसका अर्थ है कि आप और आपके डॉक्टर दोनों को पता होगा कि आप कौन सा उपचार प्राप्त कर रहे हैं।.
What are 'Phase 2' and 'Phase 3' studies?
Phase 2 studies check if a new treatment works and is safe. Phase 3 studies compare it to existing treatments to see if it's better.
क्या मैं भाग लेना बंद कर सकता हूँ अगर मैं चाहूँ?
Yes, you can leave the study at any time, and it won't affect your regular medical care.
और अधिक जानने के लिए कैसे पता करें
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.